Research programme: topical anti-infective therapeutics - ProMore

Drug Profile

Research programme: topical anti-infective therapeutics - ProMore

Alternative Names: PXL 150; PXL-181

Latest Information Update: 30 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pergamum
  • Developer ProMore Pharma
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Skin and soft tissue infections

Most Recent Events

  • 30 Sep 2016 Promore Pharma announces intention to submit IND (Promore Pharma pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Burns in India
  • 05 Jul 2016 Pergamum is now called ProMore Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top